Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer types

Abstract

Aim: As intrinsic resistance - often driven by concurrent genomic alterations in tumor suppressor genes or oncogenes - remains a major challenge in oncology, this work aimed to comprehensively analyze BRAF somatic alterations across cancer types and identify new potential therapeutic strategies to overcome drug resistance.

Methods: We conducted an extensive analysis of genomics, transcriptomics, and clinical data retrieved from public repositories, including cBioPortal. Our comprehensive analysis examined BRAF alterations [point mutations, structural variants (SVs) and copy number alteration] in more than 217,000 tumor samples across 120 distinct tumor types from primary and metastatic sites in both adult and pediatric cohorts, focusing on mutual exclusivity and co-occurrence of mutations in other oncogenes or tumor suppressors. The work also explores the association of BRAF somatic alterations with survival, clinical and molecular features.

Results: Analysis of mutation frequencies across cancer types revealed that BRAFV600E represents approximately 90% of all BRAF alterations. While melanoma and thyroid carcinoma show the highest prevalence of BRAF mutations, followed by colorectal and non-small cell lung cancer in terms of absolute number of patients harboring BRAF mutations worldwide, notably high mutation frequencies were identified in rare malignancies, including hairy-cell leukemia, ganglioglioma, and serous borderline ovarian tumors. The comprehensive analysis of genomic profiling data across these tumors uncovered distinct patterns of co-occurring and mutually exclusive alterations in oncogenes and tumor suppressor genes, illuminating resistance mechanisms and suggesting novel therapeutic combinations.

Conclusion: Comprehensive genomic profiling is critical for optimizing targeted therapy and overcoming drug resistance in BRAF-mutated cancers. The identification of co-occurring alterations provides opportunities for rational combination therapies, emphasizing the importance of detailed mutation profiling in developing effective treatment strategies across diverse cancer types.

Keywords

BRAF-mutated tumors / drug resistance / targeted therapy / genomic profiling / mutation co-occurrence / mutually exclusive mutations

References

[1] Singh AK,Kumar A.Challenges and opportunities in the crusade of BRAF inhibitors: from 2002 to 2022.ACS Omega2023;8:27819-44 PMCID:PMC10413849

[2] Śmiech M,Kono H,Taniguchi H.Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks.Genes2020;11:1342 PMCID:PMC7697059

[3] Cantwell-Dorris ER,Sheils OM.BRAF^V600E: implications for carcinogenesis and molecular therapy.Mol Cancer Ther2011;10:385-94

[4] Aprile M,Perfetto C,Ciccodicola A.Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype.Br J Cancer2023;129:249-65 PMCID:PMC10338540

[5] Brummer C,Bruss C.Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.Cancer Lett2019;442:453-63

[6] Kang HB,Lin R.Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling.Mol Cell2015;59:345-58 PMCID:PMC4530073

[7] Parmenter TJ,Kinross KM.Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.Cancer Discov2014;4:423-33 PMCID:PMC4110245

[8] Pakneshan S,Smith RA.Clinicopathological relevance of BRAF mutations in human cancer.Pathology2013;45:346-56

[9] Tran B,Tie J.Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.Cancer2011;117:4623-32 PMCID:PMC4257471

[10] Yao Z,Rodrik-Outmezguine VS.Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.Nature2017;548:234-8 PMCID:PMC5648058

[11] Dankner M,Rajkumar S,Watson IR.Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.Oncogene2018;37:3183-99

[12] Zaman A,Bivona TG.Targeting oncogenic BRAF: past, present, and future.Cancers2019;11:1197 PMCID:PMC6721448

[13] Paraiso KH,Rebecca VW.PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.Cancer Res2011;71:2750-60 PMCID:PMC3070772

[14] Cao JZ,Liu F.TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Aging2022;14:2868-79 PMCID:PMC9004558

[15] Janku F,Tsimberidou AM.PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.PLoS One2011;6:e22769 PMCID:PMC3146490

[16] Morkel M,Bläker H.Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Oncotarget2015;6:20785-800 PMCID:PMC4673229

[17] Bruijn I, Kundra R, Mastrogiacomo B, et al; AACR Project GENIE BPC Core Team, AACR Project GENIE Consortium. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal.Cancer Res2023;83:3861-7 PMCID:PMC10690089

[18] Gao J,Dogrusoz U.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.Sci Signal2013;6:pl1 PMCID:PMC4160307

[19] Cerami E,Dogrusoz U.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.Cancer Discov2012;2:401-4 PMCID:PMC3956037

[20] Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.Nat Protoc2009;4:44-57

[21] Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.Nucleic Acids Res2009;37:1-13 PMCID:PMC2615629

[22] Kanehisa M.KEGG: kyoto encyclopedia of genes and genomes.Nucleic Acids Res2000;28:27-30 PMCID:PMC102409

[23] Snyder A,Merghoub T.Genetic basis for clinical response to CTLA-4 blockade in melanoma.N Engl J Med2014;371:2189-99 PMCID:PMC4315319

[24] Faltas BM,Tagawa ST.Clonal evolution of chemotherapy-resistant urothelial carcinoma.Nat Genet2016;48:1490-9 PMCID:PMC5549141

[25] Abida W,Heller G.Genomic correlates of clinical outcome in advanced prostate cancer.Proc Natl Acad Sci U S A2019;116:11428-36 PMCID:PMC6561293

[26] Grasso CS,Robinson DR.The mutational landscape of lethal castration-resistant prostate cancer.Nature2012;487:239-43 PMCID:PMC3396711

[27] Catalanotti F,Shoushtari AN.PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma.JCO Precis Oncol2017;1:PO.16.00054 PMCID:PMC7446400

[28] Battaglin F,Lenz HJ.Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.Clin Adv Hematol Oncol2018;16:735-45 PMCID:PMC7493692

[29] Weisenberger DJ,Campan M.CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.Nat Genet2006;38:787-93

[30] Shire NJ,Golozar A.STK11 (LKB1) mutations in metastatic NSCLC: prognostic value in the real world.PLoS One2020;15:e0238358 PMCID:PMC7470384

[31] Ferenczi K,Istenes I.Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the department of internal medicine and oncology, semmelweis university.Pathol Oncol Res2023;29:1611378 PMCID:PMC10663343

[32] Dietrich S,Endris V.BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.Blood2016;127:2847-55

[33] Maitre E,Troussard X.Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.Front Oncol2022;12:1068981 PMCID:PMC9815161

[34] Paillassa J,Belarbi Boudjerra N.Recommendations for the management of patients with hairy-cell leukemia and hairy-cell leukemia-like disorders: a work by french-speaking experts and french innovative leukemia organization (FILO) group.Cancers2024;16:2185 PMCID:PMC11201647

[35] Blay JY,Mansard S.Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF^V600-mutated melanoma.ESMO Open2023;8:102038 PMCID:PMC10774964

[36] Sama S,Savage T.Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer.Gynecol Oncol Rep2024;53:101412 PMCID:PMC11109349

[37] Lima B,Sousa S,Pereira D.Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.Gynecol Oncol Rep2022;40:100942 PMCID:PMC8873542

[38] Moujaber T, Etemadmoghadam D, Kennedy CJ, et al; Australian Ovarian Cancer Study. BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition. JCO Precis Oncol. 2018;2:1-14.

[39] Combe P,Lefrère-Belda MA.Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.Invest New Drugs2015;33:1267-70

[40] Subbiah V,Wainberg ZA.Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.Nat Med2023;29:1103-12 PMCID:PMC10202803

[41] Ogino S,Kirkner GJ.CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.Gut2009;58:90-6 PMCID:PMC2679586

[42] André T, Shiu KK, Kim TW, et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207-18.

[43] Lee HM,Morris VK.Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAF^V600E-mutated colorectal cancer.Clin Cancer Res2024;30:5166-79 PMCID:PMC11829253

[44] Li Q,Luo H.Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.Signal Transduct Target Ther2024;9:266 PMCID:PMC11456611

[45] Gouda MA.Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.ESMO Open2023;8:100788 PMCID:PMC9984800

[46] Prahallad A,Huang S.Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.Nature2012;483:100-3

[47] Wang Z,Ye CY.Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): an open-label, single-arm, phase II trial.Eur J Cancer2022;163:152-62

[48] Kopetz S,Morris VK.Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).J Clin Oncol2021;39:285-94 PMCID:PMC8462593

[49] Subbiah V,Blay JY.Pan-cancer efficacy of vemurafenib in BRAF^V600-mutant non-melanoma cancers.Cancer Discov2020;10:657-63 PMCID:PMC7196502

[50] Kopetz S,Yaeger R.Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.N Engl J Med2019;381:1632-43

[51] Tabernero J,Van Cutsem E.Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study.J Clin Oncol2021;39:273-84 PMCID:PMC8078423

[52] Kopetz S,Pu J.Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Nat Med2024;30:3261-71 PMCID:PMC11564101

[53] Oikonomou E,Goulielmaki M.BRAF vs RAS oncogenes: are mutations of the same pathway equal?.Oncotarget2014;5:11752-77 PMCID:PMC4322985

[54] Deshwar A,Andreatos N.Double KRAS and BRAF mutations in surgically treated colorectal cancer liver metastases: an international, multi-institutional case series.Anticancer Res2018;38:2891-5

[55] Nunes L,Kryeziu K.Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer.Mol Cancer2024;23:264 PMCID:PMC11587607

[56] Pilié PG,Mills GB.State-of-the-art strategies for targeting the DNA damage response in cancer.Nat Rev Clin Oncol2019;16:81-104 PMCID:PMC8327299

[57] Choi W.Therapeutic targeting of DNA damage response in cancer.Int J Mol Sci2022;23:1701 PMCID:PMC8836062

[58] Pike KG,Cadogan E.The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).J Med Chem2018;61:3823-41

[59] Tozaki Y,Kato R.The combination of ATM and Chk1 inhibitors induces synthetic lethality in colorectal cancer cells.Cancers2023;15:735 PMCID:PMC9913148

[60] Li C,Tu J.ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I.Cell Death Dis2024;15:519 PMCID:PMC11271473

[61] Liu Z,Dang Q.Genomic alteration characterization in colorectal cancer identifies a prognostic and metastasis biomarker: FAM83A|IDO1.Front Oncol2021;11:632430 PMCID:PMC8093579

[62] Zhao M,Deng CX.The role of TGF-β/SMAD4 signaling in cancer.Int J Biol Sci2018;14:111-23 PMCID:PMC5821033

[63] Ivanov AA,Fu H.Targeting protein-protein interactions as an anticancer strategy.Trends Pharmacol Sci2013;34:393-400 PMCID:PMC3773978

[64] Ouyang W, Niu Q, Qui M, Fu H, Du Y, Mo X. A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting SMAD4-SMAD3-DNA complex. bioRxiv 2023;bioRxiv:2023.07.15.549169. PMCID:PMC10370110

[65] Xu W,Ke D.DUSP4 directly deubiquitinates and stabilizes Smad4 protein, promoting proliferation and metastasis of colorectal cancer cells.Aging2020;12:17634-46 PMCID:PMC7521518

[66] Bakrim S,Khalid A.Recent advances and molecular mechanisms of TGF-β signaling in colorectal cancer, with focus on bioactive compounds targeting.Biomed Pharmacother2024;177:116886

[67] Li X,Tian T.TGF-β signaling in metastatic colorectal cancer (mCRC): from underlying mechanism to potential applications in clinical development.Int J Mol Sci2022;23:14436 PMCID:PMC9698504

[68] Yan N,Guo S.Efficacy of chemo-immunotherapy in metastatic BRAF-mutated lung cancer: a single-center retrospective data.Front Oncol2024;14:1353491 PMCID:PMC10865094

[69] Guisier F,Viñas F.Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018.J Thorac Oncol2020;15:628-36

[70] Dudnik E, Peled N, Nechushtan H, et al; Israel Lung Cancer Group. BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J Thorac Oncol. 2018;13:1128-37.

[71] Lee CK,Lord S.Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis.JAMA Oncol2018;4:210-6 PMCID:PMC5838598

[72] Peng P,Hu J,Lv J.Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients.Ann Transl Med2021;9:1321 PMCID:PMC8422152

[73] Kinno T,Shiraishi K.Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.Ann Oncol2014;25:138-42

[74] Cardarella S,Nishino M.Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.Clin Cancer Res2013;19:4532-40 PMCID:PMC3762878

[75] Qu J,Li Y.Clinical characteristics, co-mutations, and treatment outcomes in advanced non-small-cell lung cancer patients with the BRAF-V600E mutation.Front Oncol2022;12:911303 PMCID:PMC9257040

[76] Myall NJ,Wood D.Natural disease history, outcomes, and co-mutations in a series of patients with BRAF-mutated non-small-cell lung cancer.Clin Lung Cancer2019;20:e208-17 PMCID:PMC6387831

[77] Kron A,Michels S.Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: results of the network genomic medicine.Ann Oncol2017;28:v461-2

[78] Planchard D,Groen HJM.Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis.J Thorac Oncol2022;17:103-15

[79] Lankenau MA,Liyanarachchi S.MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.Proc Natl Acad Sci U S A2015;112:E6744-51 PMCID:PMC4679059

[80] Wang H,Wei H.Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal Transduct Target Ther2023;8:92 PMCID:PMC9977964

[81] Kastenhuber ER.Putting p53 in context.Cell2017;170:1062-78 PMCID:PMC5743327

[82] Santarpia M,Spagnolo CC.Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.Transl Lung Cancer Res2023;12:346-68 PMCID:PMC9989806

[83] Ragnum HB,Lie AK.The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer.Br J Cancer2015;112:382-90 PMCID:PMC4453458

[84] Buffa FM,West CM.Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene.Br J Cancer2010;102:428-35 PMCID:PMC2816644

[85] Winter SC,Silva P.Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers.Cancer Res2007;67:3441-9

[86] Kikuchi H,Zeng M,Chung DC.Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.Cancer Res2009;69:8499-506 PMCID:PMC2811371

[87] Kumar SM,Edwards R.Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.Cancer Res2007;67:3177-84

[88] Zhang C,Wang J.The interplay between tumor suppressor p53 and hypoxia signaling pathways in cancer.Front Cell Dev Biol2021;9:648808 PMCID:PMC7930565

[89] Sethi N,McFarland J.Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma.JCI Insight2019;4:128439 PMCID:PMC6693823

[90] Chen Y,Liu X,Yi P.Potential therapies targeting nuclear metabolic regulation in cancer.MedComm2023;4:e421 PMCID:PMC10685089

[91] Gouda MA.Expanding the benefit: dabrafenib/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors.Am Soc Clin Oncol Educ Book2023;43:e404770

[92] Thein KZ,Park BS.Target-driven tissue-agnostic drug approvals-a new path of drug development.Cancers2024;16:2529 PMCID:PMC11274498

[93] Mun J.The hallmarks of tissue-agnostic therapies and strategies for early anticancer drug discovery.Drug Discov Today2024;29:104203

[94] Bohn JP,Wanner D.Low-dose vemurafenib in hairy cell leukemia patients with active infection.Am J Hematol2019;94:E180-2 PMCID:PMC6593695

[95] Kim CW,Kim C.Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer.Cancers2021;13:4906 PMCID:PMC8507875

[96] Tian J,Chao SX.Combined PD-1, BRAF and MEK inhibition in BRAF^V600E colorectal cancer: a phase 2 trial.Nat Med2023;29:458-66 PMCID:PMC9941044

[97] Van Cutsem E,Grothey A.Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study.J Clin Oncol2019;37:1460-9 PMCID:PMC7370699

[98] Gallois C,Auclin É.Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.ESMO Open2024;9:103696 PMCID:PMC11415680

[99] Auliac JB,Do P.Efficacy of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019.Cancers2020;12:3608 PMCID:PMC7761573